<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04609969</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO-2020-18</org_study_id>
    <nct_id>NCT04609969</nct_id>
  </id_info>
  <brief_title>Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test</brief_title>
  <acronym>COVID-VIRO</acronym>
  <official_title>Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test on Nasopharyngeal Specimens i</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current prospective study was designed to assess the diagnostic specificity and&#xD;
      sensitivity of a novel antigen-based rapid detection test (COVID-VIRO®) on nasopharyngeal&#xD;
      specimens in comparison to the reference test in a real-life setting&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Two nasopharyngeal swab specimens will be concurrently collected on:&#xD;
&#xD;
        -  adult patients hospitalized in the Infectious Diseases Department of the Centre&#xD;
           Hospitalier Régional d'Orléans (CHRO) for confirmed SARS-CoV-2 infection,&#xD;
&#xD;
        -  or symptomatic or asymptomatic subjects voluntarily accessing the COVID-19 Screening&#xD;
           Department of the CHRO to perform a diagnostic test. COVID VIRO® diagnostic.&#xD;
&#xD;
      Specificity and sensitivity are assessed in comparison to real-time RT-qPCR results.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Actual">October 17, 2020</completion_date>
  <primary_completion_date type="Actual">October 17, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of COVID VIRO® diagnostic specificity</measure>
    <time_frame>Month 1</time_frame>
    <description>COVID-VIRO® specificity is calculated using the RT-qPCR results as reference test, according to the following formulas:&#xD;
Specificity (%) = 100 x [Negative / (Negative + Positive)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of COVID VIRO® diagnostic sensitivity</measure>
    <time_frame>Month 1</time_frame>
    <description>COVID-VIRO® sensitivity is calculated using the RT-qPCR results as reference test, according to the following formulas:&#xD;
Sensitivity (%) = 100 x [Positive/ (Positive + Negative)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of COVID VIRO® diagnostic sensitivity for RT-qPCR Cycle threshold value &lt; or &gt; 28</measure>
    <time_frame>Month 1</time_frame>
    <description>COVID-VIRO® sensitivity is calculated using the RT-qPCR results, restricting for Cycle threshold value</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Comparison between RT-qPCR and COVID-VIRO® results on nasopharyngeal swab specimens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>RT-qPCR test</intervention_name>
    <description>Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.</description>
    <arm_group_label>Comparison between RT-qPCR and COVID-VIRO® results on nasopharyngeal swab specimens</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>COVID-VIRO® test</intervention_name>
    <description>Two concurrent nasopharyngeal swab specimens are collected for each participant. Comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR positive patients is used to assess COVID-VIRO® sensitivity. Conversely, comparison between RT-qPCR and COVID-VIRO® results of RT-qPCR negative patients is used to assess COVID-VIRO® specificity.</description>
    <arm_group_label>Comparison between RT-qPCR and COVID-VIRO® results on nasopharyngeal swab specimens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (&gt;18 years old) already having a SARS-CoV-2 RT-qPCR positive result&#xD;
             within 5 days&#xD;
&#xD;
          -  Adult patients (&gt;18 years old) requiring a SARS-CoV-2 RT-qPCR on nasopharyngeal swab&#xD;
             specimen for any reason&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients non wishing to participate&#xD;
&#xD;
          -  Under guardianship or curatorship or safeguard of justice patients&#xD;
&#xD;
          -  Inability to join the hospital other than by public transport&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry PRAZUCK, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR ORLEANS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'Orléans, France</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://covid19.who.int/</url>
    <description>WHO coronavirus Dashboard on Sept 15th,2020</description>
  </link>
  <link>
    <url>https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19</url>
    <description>France Epidemiologic situation on 2020 september 20th</description>
  </link>
  <reference>
    <citation>Dramé M, Tabue Teguo M, Proye E, Hequet F, Hentzien M, Kanagaratnam L, Godaert L. Should RT-PCR be considered a gold standard in the diagnosis of COVID-19? J Med Virol. 2020 Nov;92(11):2312-2313. doi: 10.1002/jmv.25996. Epub 2020 Jul 14.</citation>
    <PMID>32383182</PMID>
  </reference>
  <reference>
    <citation>Zitek T. The Appropriate Use of Testing for COVID-19. West J Emerg Med. 2020 Apr 13;21(3):470-472. doi: 10.5811/westjem.2020.4.47370. Review.</citation>
    <PMID>32302278</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2 infection</keyword>
  <keyword>COVID19</keyword>
  <keyword>Antigen detection test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

